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Finally, it has never been studied, as in the case of platelet
aggregation, whether iPF2-III is able to amplify the vasomotor
response to other agonists. This effect should be studied in the
future before concluding that the concentration of this isoprostane
in the coronary circulation has no role in the vasospasm occurring
after PTCA.
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Percutaneous Revascularization Versus
Beating Heart CABG or CABG With
Cardiopulmonary Bypass in Patients
With Refractory Myocardial Ischemia
Morrison et al. (1) recently reported the results of a very important
multicenter randomized trial comparing percutaneous coronary
intervention (PCI) versus coronary artery bypass graft surgery
(CABG) for patients with refractory myocardial ischemia and risk
factors for adverse outcomes with CABG. It clearly appears that
PCI is an alternative to CABG for patients with medically
refractory myocardial ischemia at high risk for adverse outcomes
with CABG. Incidentally, the study was initiated in February 1995
when multivessel beating heart CABG via sternotomy was popu-
larized by Buffolo et al. (2). The study by Morrison et al. (1) does
not address the techniques used to accomplish CABG in this
study. If CABG was performed using cardiopulmonary bypass,
then the study fails to mention the cardioprotective strategies used,
as this may be an important factor in the rates of perioperative
myocardial infarction (MI) and clinical outcomes (3). Unless strict
cardioprotective criteria were used, it is indeed possible that various
surgeons from various centers used different cardioprotective strat-
egies: ventricular fibrillation versus ischemia, crystalloid versus
blood cardioplegia, antegrade versus retrograde delivery of cardio-
plegia and warm versus cold cardioplegia (3). In addition, the
methods fail to mention whether off-pump CABG was utilized,
and if so, for which type of patients. Although initial results of
off-pump CABG in low-risk patients is encouraging, patients with
high preoperative risk factors (octogenarians, recent MI, reopera-
tive CABG, left ventricular ejection fraction 40%, previous
stroke) seem to derive marked advantages from the off-pump
technique (4). Prospective randomized trials with longitudinal
clinical and angiographic follow-up are needed to better define the
real advantages and limits of this new clinical strategy in all
patients, especially in high-risk groups. Preliminary data at mid-
term follow-up is very encouraging for coronary revascularization
on the beating heart (5–8).
Finally, if these studies are further corroborated, then the
surgical strategy itself (beating heart versus traditional CABG
using cardiopulmonary bypass) may prove to be an additional
factor in comparisons of revascularization methods in high-risk
patients. We commend Morrison et al. (1) for conducting a very
important and timely study.
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